Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: Results of Dutch Childhood Leukemia Study Group protocol ALL-7 (1988-1991)

Blood

Volumn 94, Issue 4, 1999, Pages 1226-1236

  Kamps, W A ^a   Bokkerink J P M ^b   Hahlen K ^b   Hermans, J ^b   Riehm, H ^b   Gadner, H ^b   Schrappe, M ^b   Slater, R ^b   Van Den Berg De Ruiter, E ^b   Smets, L A ^b   De Vaan, G A M ^b   Weening, R S ^b   Van Weerden, J F ^b   Van Wering, E R ^b   Van Der Does Van Den Berg, A ^b  

^a DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEOXYTHIOGUANOSINE; DEXAMETHASONE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; META ANALYSIS; NETHERLANDS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT PLANNING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; RECURRENCE; TREATMENT OUTCOME;

EID: 0344994550     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Reiter A, Schrappe M, Ludwig W, Hiddemann W, Sauter S, Henze G, Zimmermann M, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM-86. Blood 84:3122, 1994
2. Veerman AJP, Hählen K, Kamps WA, Van Leeuwen EF, De Vaan GAM, Solbu G, Suciu S, Van Wering ER, Van der Does-van den Berg A: High cure rate with a moderately intensive treatment regiment in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911, 1996
3. Riehm H, Gadner H, Henze G, Langermann HJ, Odenwald E: The Berlin Childhood Acute Lymphoblastic Leukemia Therapy Study, 1970-1976. Am J Pediatr Hematol Oncol 2:299, 1980
4. Henze G, Langermann HJ, Brämswig J, Breu H, Gadner H, Schellong G, Weite K: Ergebnisse der Studie BFM 1976-1979 zur Behandlung der Jugendlichen. Klin Pädiatr 193:145, 1981
5. Henze G, Langermann HJ, Fengler R, Brandeis M, Evers KG, Gadner H, Hinderfeld L, Jobke A, Kornhuber B, Lampen F, Lasson U, Ludwig R, Müller-Weihreich S, Neidhardt M, Nessler G, Niethammer D, Rister M, Ritter J, Schaaf A, Schellong G, Stollmann B, Treuner J, Wahlen W, Weinel P, Wehninger H, Riehm H: Therapiestudie BFM 79/81 zur Behandlung der akuten lymphoblas tischen Leukämie bei Kindern und Jugendlichen: Intensive Reinduktions therapie für Patientengruppen mit unterschiedlichem Rezidivrisiko. Klin Pädiatr 194:195, 1982
6. Van der Does-van den Berg A, Van Wering ER, Suciu S, Solbu G, Van 't Veer MB, Rammeloo JA, De Koning J, Van Zanen GE: Effectiviness of rubidomy cine induction therapy with vincristine, prednisone and L-asparaginase for standard risk childhood acute lymphocytic leukemia: Results of a Dutch Phase III study (ALL V). Am J Pediatr Hematol Oncol 11:125, 1989
7. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. Br J Haematol 33:451, 1976
8. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C; The French-American-British (FAB) Cooperative Group: The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol 47:553, 1981
9. Veerman AJP, Huismans DR, Van Zantwijk CH: Storage of cerebrospinal fluid samples at room temperature. Acta Cytol 29:188, 1985
10. Van Wering ER, Veerman AJP, Van der Linden-Schrever BEM: Diagnosis of meningeal involvement in childhood acture lymphoblastic leukemia: Cytomorphology and TdT. Eur J Haematol 40:250, 1988
11. Riehm H, Feickert HJ, Schrappe M, Henze G, Schellong G: Therapy results in five ALL-BFM studies since 1970. Complications of risk factors for prognosis. Haematol Blood Transfus 30:139, 1987
12. Langermann HJ, Henze G, Wulf M, Riehm H: Abschätzung der Tumorzellmasse bei der akuten lymphoblastischen Leukämie im Kindersalter: Prognostische Bedeutung und praktische Anwendung. Klin Pädiatr 194:209, 1982
13. Van Wering ER, Brederoo P, Van Staalduinen GJ, Van Wering ER, Van der Meulen J, Van der Linden-Schrever BEM, Van Dongen JJM: Contribution of electronmicroscopy to the classification of the minimally differentiated leukemias in children. Recent Results Cancer Res 131:77, 1993
14. Slater RM, Smeets DFCM, Hagemeijer A, De Jong B, Beverstock CG, Geraedts JPM, Van der Does-van den Berg A, Van Wering ER, Veerman AJP: Update of the cytogenetic study of childhood non-high-risk acute lymphocytic leukemia at diagnosis in protocol VI of the Dutch Childhood Leukemia Study Group. Haematol Blood Transfus 33:169, 1990
15. Smets LA, Slater R, Van Wering ER, Van der Does-van den Berg A, Hart AAM, Veerman AJP, Kamps WA: DNA index and % S-phase cells determined in acute lymphoblastic leukemia of children: A report from Studies ALL V, ALL VI and ALL VII (1979-1991) of the Dutch Childhood Leukemia Study Group and The Netherlands Workgroup for Cancer Genetics and Cytogenetics. Med Pediatr Oncol 25:437, 1995
16. Matthews DE, Farewell VT: Understanding and Using Medical Statistics (ed 3). Basel, Switzerland, Karger, 1996
17. Klein JP, Moeschberger ML: Survival Analysis. Berlin, Germany, Springer, 1997
18. Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D, Reiter A, Schellong G: Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus 33:439, 1990
19. Conter V, Schrappe M, Aricò M, Reiter A, Rizzari C, Dördelmann M, Valsecchi MG, Zimmermann M, Ludwig W-D, Basso G, Masera G, Riehm H, for the Associazone Italiana Ematologia Oncologia Pedriatrica and the Berlin-Frankfurt-Munster Groups: Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. J Clin Oncol 15:2786, 1997
20. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack D: Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to prevention of meningeal leukemia. J Clin Oncol 5:202, 1987
21. Kaspers GJL, Veerman AJP, Popp-Snijders C, Lomecky M, Van Zantwijk CH, Swinkels LMJW, Van Wering ER, Pieters R: Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 27:114, 1996
22. Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kuhl J, Gadner H, Havers W, Pluss H, Kornhuber B, Zintl F, Ritter J, Urban C, Niethammer D, Riehm H: Prevention of CNS recurrence in childhood ALL: Results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. Klin Padiatr 210:192, 1998
23. 2) and without radiotherapy in childhood ALL patients with intermediate risk using a BFM type protocol. Proc Am Soc Clin Oncol 15:369, 1996
24. Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, Mori PG, Miniero R, Colella R, Basso G, Rondelli R, Pession A, Masera G: Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS-relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster based intensive chemothera py. J Clin Oncol 13:2495, 1995
25. Stark B, Abramov A, Atties D, Balin A, Burstein Y, Chividalli G, Rechavi A, Ramu N, Sharon R, Sthoeger D, Zaizov R: Successful CNS prevention with the modified BFM-86 in non-high risk (NHR) ALL in children with extended intrathecal-triple (ITT) in the Israëli National Study (ISN)'89. Ann Haematol 74:A41, 1997 (abstr)
26. Pullen J, Boyett J, Shuster J, Crist W, Land V, Frankel L, Iyer R, Backstrom L, Vaneys J, Harris H, Ravindranath Y, Sullivan M: Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia. J Clin Oncol 11:839, 1993
27. Nachman J, Sather HN, Cheriow JM, Sensel MG, Gaynon PS, Lukens JN, Wolff L, Trigg ME: Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group. J Clin Oncol 16:920, 1998
28. Ochs J, Mulhern R, Fairclough D, Parvey L, Whitaker J, Ch'ien L, Mauer A, Simone J: Comparison of neuropsychological functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: A prospective study. J Clin Oncol 9:145, 1991
29. Hertzberg H, Huk WJ, Ueberall MA, Langer T, Meier W, Dopfer R, Skalej M, Lackner H, Bode U, Janssen G, Zintl F, Beck JD, for the German Late Effects Working Group: CNS late effects after ALL therapy in childhood. Part 1: Neuroradiological findings in long-term survivors of childhood ALL an evaluation of the interferences between morphology and neuropsychological performance. Med Pediatr Oncol 28:387, 1997
30. Pui CH, Crist WM, Look AT: Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 76:1449, 1990
31. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch ML, Mirro J, Ochs JS, Look AT, Williams DL, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM: Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61, 1991
32. Rubin CM, Le Beau MM, Mick R, Bitter MA, Nachman J, Rudinsky R, Appel HJ, Morgan E, Suarez CR, Schumacher HR, Subramanian K, Rowley JD: Impact of chromosomal translocations on prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 9:2183, 1991
33. Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, Crist WM, Pui CH: Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 86:1292, 1995
34. Kaspers GJL, Veerman AJP, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, Van der Does-van den Berg A: In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90:2723, 1997
35. Richards S, Gray R, Peto R, Gaynon P, Masera G: Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12000 randomised children. Lancet 347:1783, 1996
36. Van Dongen JJM, Seriu T, Panzer-Grümayer R, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig W-D, Basso G, de Bruijn MAC, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WCJ, Riehm H, Bartram C: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352: 1731, 1998
37. Pinkel D: Five-year follow-up of "total therapy" of childhood lymphoblastic leukemia. JAMA 216:648, 1971
38. Van der Does-van den Berg A, Veerman AJP, van Wering ER, de Vries JA, de Waal FC, van Zanen GE, Kamps WA: Childhood acute lymphoblastic leukemia in The Netherlands. Randomized studies and nationwide treatment results from 1972 to 1995. Int J Pediatr Hematol Oncol 5:125, 1998